Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes.

Journal of the American Medical Informatics Association : JAMIA - 1 Jul 2016

Cheng Feixiong, Zhao Junfei, Fooksa Michaela, Zhao Zhongming

Abstract excerpt

OBJECTIVE: Development of computational approaches and tools to effectively integrate multidomain data is urgently needed for the development of newly targeted cancer therapeutics. METHODS: We proposed an integrative network-based infrastructure to identify new druggable targets and anticancer indications for existing drugs through targeting significantly mutated genes (SMGs) discovered in the human cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Databases, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Drug Repositioning

Share to Gene Regulatory Networks

Share to Genome, Human

Share to Neoplasms

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 27026610
DOI: 10.1093/jamia/ocw007
PMCID: PMC6370253

Genes

ASPM
CTTN
EIF4G1
FOXP1
STIP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes.PMID 27026610Read ↗

A Co-essentiality Network of Cancer Driver Genes Better Prioritizes Anticancer DrugsSemantic proximity Read ↗

Systems Pharmacology-Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes.Semantic proximity Read ↗

Identification of important genes and drug repurposing based on clinical-centered analysis across human cancers.Semantic proximity Read ↗

Integration of genetic variants and gene network for drug repurposing in colorectal cancer.Semantic proximity Read ↗

Computational drug repositioning through heterogeneous network clustering.Semantic proximity Read ↗

GRAND: A database of gene regulatory network models across human conditionsSemantic proximity Read ↗

Disease networks and their contribution to disease understanding and drug repurposing: Evolution of the concept, techniques and data sourcesSemantic proximity Read ↗

An Integrated Knowledge Graph and Network Medicine Pipeline for Drug Repurposing: Benchmarking Across Human Diseases and Application to Amyotrophic Lateral SclerosisSemantic proximity Read ↗

Utilizing Pre-trained Network Medicine Models for Generating Biomarkers, Targets, Re-purposing Drugs, and Personalized Therapeutic Regimes: COVID-19 ApplicationsSemantic proximity Read ↗

GARD: Genomic Data based Drug Repurposing in Head and Neck Cancer with Large Language Model ValidationSemantic proximity Read ↗

MUSTARD-a comprehensive resource of mutation-specific therapies in cancer.Semantic proximity Read ↗

Cancer-Alterome: a literature-mined resource for regulatory events caused by genetic alterations in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.